Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05111509 · ClinicalTrials.gov registry record · Early Phase 1
A First-in-human Clinical Trial to Evaluate an Alpha-radiation Imaging Agent
A Early Phase 1 study of Neuroendocrine Tumor Grade 2 and Neuroendocrine Tumor Grade 1, sponsored by Yusuf Menda.
- Active
- Registry status
- Early Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT05111509: Active Early Phase 1 study of Neuroendocrine Tumor Grade 2 and Neuroendocrine Tumor Grade 1, sponsored by Yusuf Menda.
NCT05111509 is a Early Phase 1 study of Neuroendocrine Tumor Grade 2 and Neuroendocrine Tumor Grade 1 that is active but no longer recruiting, run by Yusuf Menda. The registered enrollment target is 20 participants, below the 71-participant average among 3 other Neuroendocrine Tumor Grade 2 trials with a reported enrollment target (72% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05111509, a Early Phase 1 study of Neuroendocrine Tumor Grade 2 and Neuroendocrine Tumor Grade 1, is active but no longer recruiting, sponsored by Yusuf Menda.
- ACTIVE NOT RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a first in man study to determine if \[203Pb\]VMT-α-NET identifies neuroendocrine tumors with SPECT/CT. This is the first step to testing \[212Pb\]-based alpha radiation therapy in neuroendocrine therapy.
Primary Outcome
percentage of lesions detected with \[203Pb\]VMT-α-NET compared to the gold standard of NetSPOT or Ga-68 DOTATOC.
Conditions Studied
Interventions
- DRUG [203Pb]VMT-α-NET
- DEVICE SPECT/CT
Study Locations (1)
Iowa
- The University of Iowa - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2022-08-22 |
| Est. Completion | 2026-06-30 |
| Phase | Early Phase 1 |
What the registry record for NCT05111509 still lists
NCT05111509 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 71-participant average among 3 other Neuroendocrine Tumor Grade 2 trials with a reported enrollment target (72% lower).
The record links to 2 conditions, with Neuroendocrine Tumor Grade 2 appearing as the primary indexed condition, and to 2 interventions - of which [203Pb]VMT-α-NET is the first listed.
NCT05111509 reports a single indexed study location in Iowa.
Frequently Asked Questions
What is clinical trial NCT05111509 about?
NCT05111509 is a clinical study titled "A First-in-human Clinical Trial to Evaluate an Alpha-radiation Imaging Agent". This is a first in man study to determine if \[203Pb\]VMT-α-NET identifies neuroendocrine tumors with SPECT/CT. This is the first step to testing \[212Pb\]-based alpha radiation therapy in neuroendocrine therapy.
What is the current status of trial NCT05111509?
This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 20 participants. The study started on 2022-08-22. Estimated completion is 2026-06-30.
What conditions does trial NCT05111509 study?
This clinical trial studies the following conditions: Neuroendocrine Tumor Grade 2, Neuroendocrine Tumor Grade 1.
What interventions are being tested in trial NCT05111509?
The interventions under investigation include: [203Pb]VMT-α-NET (DRUG), SPECT/CT (DEVICE).
Who is sponsoring clinical trial NCT05111509?
This trial is sponsored by Yusuf Menda, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05111509 being conducted?
This trial has 1 study location across Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuroendocrine Tumor Grade 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI